Tetraphase Pharmaceuticals (NASDAQ:TTPH) Share Price Crosses Below 200 Day Moving Average of $0.00

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as low as $0.44. Tetraphase Pharmaceuticals shares last traded at $0.44, with a volume of 600 shares changing hands.

TTPH has been the subject of a number of research reports. ValuEngine lowered Yext from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 10th. HC Wainwright increased their price target on Cytokinetics from $21.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, May 6th. SunTrust Banks set a $37.00 price target on Yelp and gave the company a “hold” rating in a research note on Friday, May 10th. Zacks Investment Research lowered G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of SCYNEXIS in a research note on Sunday, May 12th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $4.08.

The company has a debt-to-equity ratio of 0.53, a current ratio of 7.28 and a quick ratio of 7.10. The firm has a 50 day simple moving average of $0.65.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. The business had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.93 million. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%. Sell-side analysts anticipate that Tetraphase Pharmaceuticals Inc will post -1.41 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TTPH. Deutsche Bank AG boosted its stake in shares of Tetraphase Pharmaceuticals by 890.0% during the 4th quarter. Deutsche Bank AG now owns 1,040,447 shares of the biopharmaceutical company’s stock worth $1,174,000 after acquiring an additional 935,349 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Tetraphase Pharmaceuticals by 54.1% in the fourth quarter. Two Sigma Investments LP now owns 785,950 shares of the biopharmaceutical company’s stock valued at $888,000 after purchasing an additional 275,944 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Tetraphase Pharmaceuticals by 45.4% in the first quarter. Acadian Asset Management LLC now owns 560,225 shares of the biopharmaceutical company’s stock valued at $750,000 after purchasing an additional 174,939 shares in the last quarter. Edmond DE Rothschild Holding S.A. lifted its holdings in shares of Tetraphase Pharmaceuticals by 90.9% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 100,000 shares in the last quarter. Finally, 683 Capital Management LLC lifted its holdings in shares of Tetraphase Pharmaceuticals by 10.6% in the fourth quarter. 683 Capital Management LLC now owns 790,571 shares of the biopharmaceutical company’s stock valued at $893,000 after purchasing an additional 75,474 shares in the last quarter. 38.67% of the stock is owned by institutional investors and hedge funds.

Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Further Reading: What is the quiet period?

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.